Game On: Medicare Will Parry Manufacturer Efforts To Sidestep Price Negotiation, Guidance Says
Executive Summary
CMS will need to continue to be ‘savvy’ to strategies brand manufacturers already employ to shape the landscape for generic and biosimilar competition, policy expert says.
You may also be interested in...
Amgen Biosimilar For Stelara May Face Price Drop In Medicare Shortly After Launch; What’s A Follow-On To Do?
With J&J's Stelara set for Medicare negotiation, the fate of Amgen’s new ustekinumab interchangeable be a test case for concerns that the pricing program will significantly undercut incentives for developing biosimilars for blockbusters in the Medicare market.
Piling On: AstraZeneca Files Sixth Manufacturer Lawsuit Against Medicare Negotiation Program
Firm leans into allegations that the US government violated the Administrative Procedures Act in implementing the program. More legal actions are expected from industry once CMS announces the first list of drugs subject to negotiation. Our lawsuit tracker will keep you apprised.
Piling On: AstraZeneca Files Sixth Manufacturer Lawsuit Against Medicare Negotiation Program
Firm leans into allegations that the US government violated the Administrative Procedures Act in implementing the program. More legal actions are expected from industry once CMS announces the first list of drugs subject to negotiation. Our lawsuit tracker will keep you apprised.